Elanco
ELAN
$23.63
-4.37%
Elanco Animal Health is a global animal health company that develops, manufactures, and markets pharmaceutical products for both companion animals (pet health) and food animals (cattle, poultry, swine, and sheep). As a major player in the specialty drug manufacturing industry, the company has built its scale through a series of strategic acquisitions, including Bayer Animal Health, positioning it as one of the world's largest pure-play animal health businesses. The current investor narrative is centered on a compelling turnaround story, as evidenced by recent news highlighting strong Q1 2026 earnings, significant product momentum, and raised guidance, suggesting the company is successfully executing its post-acquisition integration and operational improvement plans.…
ELAN
Elanco
$23.63
Related headlines
Investment Opinion: Should I buy ELAN Today?
Rating & Thesis: ELAN is a Hold for risk-tolerant investors. The core thesis is that the company is a compelling but unproven turnaround story, showing strong revenue momentum and cash flow but still grappling with inconsistent profitability, making the risk/reward balanced at current levels. The bullish analyst sentiment (e.g., Piper Sandler upgrade to 'Overweight') supports a positive view, but the lack of a consensus price target underscores the uncertainty.
Supporting Evidence: The forward P/E of 20.36x is reasonable for a company expected to return to growth, but it is predicated on achieving estimated EPS of $1.535. Revenue growth accelerated to 12.16% YoY in Q4 2025, a positive sign. The company generates positive free cash flow ($284M TTM), providing financial flexibility. However, the bearish counterpoints are severe: a recent net loss of -$276M and gross margin compression of over 14 percentage points sequentially raise red flags about earnings quality.
Risks & Conditions: The two biggest risks are 1) failure to return to consistent net profitability, and 2) sustained gross margin pressure. This Hold rating would upgrade to a Buy if the company demonstrates two consecutive quarters of positive net income with gross margins stabilizing above 45%. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if the stock breaks below key technical support near $19.80. Relative to its own historical PS range, the stock appears fairly valued, but the valuation is entirely dependent on the forward earnings estimate materializing.
Sign up to view all
ELAN 12-Month Price Forecast
ELAN presents a classic 'show me' story. The bullish elements – accelerating revenue, positive cash flow, and reasonable forward valuation – are compelling. However, they are directly countered by bearish concerns over erratic profitability and severe gross margin compression. The high beta adds a layer of macro risk. The neutral stance reflects this balance of opportunity and risk, with the base case being a volatile range-trade as the company works to prove its earnings potential. The stance would upgrade to bullish on evidence of sustained margin improvement and consecutive profitable quarters. It would turn bearish if revenue growth decelerates or losses widen, invalidating the forward earnings estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $30.72 and implied upside of +30.0% versus the current price.
Average Target
$30.72
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$19 - $31
Analyst target range
Analyst coverage for Elanco appears limited, with only 5 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. This indicates insufficient analyst coverage is available for a robust consensus view. Limited coverage typically suggests the stock is a mid-cap name with a specialized story that may not be on all institutional radars, which can lead to higher volatility and less efficient price discovery. The available institutional ratings data shows a generally bullish tilt among those firms that do cover it, with recent actions including an upgrade from Piper Sandler to 'Overweight' and maintained 'Overweight' or 'Outperform' ratings from Keybanc, Leerink Partners, and JP Morgan, while Morgan Stanley maintains a more neutral 'Equal Weight' stance.
Bulls vs Bears: ELAN Investment Factors
The bull case for ELAN is primarily driven by accelerating revenue growth (12.16% YoY), positive free cash flow generation, and a valuation that is not stretched relative to its own history. The bear case centers on inconsistent profitability, evidenced by a large Q4 net loss of -$276M, and significant gross margin compression. Currently, the bull side has stronger evidence, as the revenue acceleration and cash flow generation are concrete signs of operational progress. However, the single most important tension in the investment debate is the disconnect between strong top-line growth and bottom-line profitability. The resolution of this tension – specifically, whether gross margins can stabilize and expand to translate revenue growth into sustained net income – will determine if this is a true turnaround story or merely a revenue recovery with ongoing profitability challenges.
Bullish
- Strong Revenue Growth Acceleration: Q4 2025 revenue grew 12.16% YoY to $1.144B, a significant acceleration from prior periods, indicating successful execution of the turnaround plan. This growth is driven by a balanced portfolio across both Farm Animal ($640M) and Pet Health ($489M) segments.
- Positive Free Cash Flow Generation: The company generated $284M in trailing twelve-month free cash flow, with $46M in Q4 2025 alone. This provides internal resources for debt service and operations, reducing reliance on external financing and supporting financial stability.
- Analyst Sentiment Bullish, Forward PE Reasonable: Institutional ratings are generally positive, with recent upgrades to 'Overweight'. The forward P/E of 20.36x, based on estimated EPS of $1.535, suggests the market is pricing in a credible return to profitability, not an overly speculative premium.
- Valuation Not Stretched Historically: The current Price-to-Sales ratio of 2.38 is near the lower end of its historical range (3.67 to 12.43). This indicates the stock is not trading at excessive valuation highs, leaving room for multiple expansion if the turnaround narrative strengthens.
Bearish
- Inconsistent Profitability & Recent Net Loss: Despite positive quarters earlier in 2025, Q4 2025 reported a significant net loss of -$276M. This volatility in earnings, with a trailing net margin of -4.92%, calls into question the sustainability of the turnaround and the path to consistent profits.
- Gross Margin Compression & Cost Pressure: Q4 2025 gross margin compressed sharply to 39.34% from 53.39% in Q3 2025, a drop of over 14 percentage points. This indicates significant cost pressures or product mix issues that could threaten the company's path to improved overall profitability.
- High Volatility & Recent Underperformance: With a beta of 1.687, ELAN is ~69% more volatile than the market. It has underperformed the SPY by -6.82% over the last 3 months, suggesting deceleration in momentum and heightened sensitivity to broader market risk-off sentiment.
- Limited Analyst Coverage & No Consensus Target: Only 5 analysts provide estimates, and no consensus price target is available. This limited coverage can lead to less efficient price discovery and higher volatility, as the investment story is less scrutinized and understood by the broader market.
ELAN Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a formidable 83.85% gain over the past year. With a current price of $24.71, the stock is trading at approximately 80% of its 52-week range ($13.16 to $27.72), indicating it is approaching the upper bounds of its recent trading band, which reflects strong momentum but also potential for near-term resistance. Recent momentum, however, shows signs of divergence; while the 1-month return is a solid +7.48%, the 3-month return is a more modest +5.78%, and the stock has underperformed the SPY by -6.82% over that 3-month period, suggesting some deceleration relative to the broader market after its powerful run. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $27.72 and support at the 52-week low of $13.16; a decisive breakout above $27.72 would signal a resumption of the primary bull trend, while a breakdown below the recent May low near $19.80 could indicate a deeper correction. The stock's high beta of 1.687 confirms it is approximately 69% more volatile than the market, a critical factor for risk management that implies larger swings in both directions.
Beta
1.70
1.70x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$13-$28
Price range past year
Annual Return
+75.9%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | -9.7% | -0.0% |
| 3m | +1.2% | +8.7% |
| 6m | +7.9% | +8.0% |
| 1y | +75.9% | +23.1% |
| ytd | +4.9% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Revenue growth is showing positive momentum, with Q4 2025 revenue of $1.144 billion representing a 12.16% year-over-year increase, a significant acceleration from the prior quarter's more modest growth. Segment data reveals the Farm Animal segment ($640 million) and Pet Health segment ($489 million) as the primary revenue drivers, indicating a balanced portfolio across both major end markets. Profitability remains a mixed but improving picture; while the company reported a net loss of -$276 million for Q4 2025, the gross margin of 39.34% showed sequential compression from the prior quarter's 53.39%, though the operating margin remained positive at 1.66%. The trajectory toward sustained profitability is the key focus, as the company has demonstrated quarters of positive net income earlier in 2025 (Q1: $67 million, Q2: $11 million). The balance sheet and cash flow position appear manageable; the company maintains a healthy current ratio of 2.17 and a moderate debt-to-equity ratio of 0.61. Importantly, it generated positive free cash flow of $46 million in Q4 2025 and $284 million on a trailing twelve-month basis, providing internal resources to fund operations and debt service without excessive reliance on external financing.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.39%
Latest Quarter
Free Cash Flow
$284000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Given the company's negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Elanco trades at a trailing PS ratio of 2.38, while its forward-looking valuation, implied by a forward PE of 20.36x based on estimated EPS of $1.535, suggests the market is pricing in a significant return to profitability and earnings growth. Compared to industry averages, data is not available in the provided set for a direct sector PS comparison, limiting the peer analysis. However, examining the stock's own historical context is revealing: the current PS ratio of 2.38 is near the lower end of its historical range observed in recent quarters, which has spanned from approximately 3.67 to 12.43 over the past few years. This positioning suggests the stock is not trading at excessive valuation highs relative to its own history, potentially leaving room for multiple expansion if the turnaround narrative continues to gain credibility and financial metrics improve consistently.
PE
-48.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -240x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's inconsistent profitability, as evidenced by a Q4 2025 net loss of -$276M and a trailing net margin of -4.92%. While free cash flow is positive ($284M TTM), the recent gross margin compression from 53.39% to 39.34% in one quarter signals potential cost inflation or unfavorable product mix that could derail the path to sustainable earnings. The company's growth narrative is heavily dependent on continuing its revenue acceleration to justify its forward P/E of 20.36x, making any deceleration a significant valuation risk.
Market & Competitive Risks: The stock's high beta of 1.687 makes it highly sensitive to broad market swings, increasing downside risk in a risk-off environment. Its valuation, while reasonable on a forward earnings basis, carries compression risk if the market loses faith in the estimated $1.535 EPS. The stock has already shown signs of losing momentum, underperforming the SPY by -6.82% over the last three months. As a mid-cap name with limited analyst coverage (only 5 analysts), it is also vulnerable to sentiment shifts and lacks the stabilizing influence of widespread institutional research.
Worst-Case Scenario: The worst-case scenario involves a failure to stabilize profitability, where gross margins remain compressed and the company posts another significant quarterly loss. This could trigger a loss of confidence in the turnaround story, leading to analyst downgrades and multiple contraction. Combined with a broader market downturn amplified by its high beta, this could see the stock re-test its 52-week low of $13.16. From the current price of $24.71, this represents a potential downside of approximately -47%.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The company's earnings are highly inconsistent, with a Q4 2025 net loss of -$276M and gross margin compression from 53.39% to 39.34%. 2) Valuation & Sentiment Risk: The stock's high beta of 1.687 makes it prone to sharp declines in a market downturn, and limited analyst coverage (5 analysts) can lead to sentiment-driven volatility. 3) Execution Risk: The entire investment thesis hinges on the company successfully executing its turnaround; any stumble in revenue growth or further margin pressure could cause a rapid derating. 4) Technical Risk: After an 84% run-up, the stock is near its 52-week high ($27.72) and faces significant resistance, increasing the chance of a pullback.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $22 and $27 as the company shows uneven progress on its turnaround. The Bull Case (30% probability), triggered by sustained profitability, targets a range of $27.72 to $32. The Bear Case (20% probability), should the turnaround fail, sees a drop to between $13.16 and $19.80. The base case is most likely, reflecting the current 'show me' phase where strong revenue growth is not yet matched by reliable profits. The key assumption is that the company will neither fully succeed nor completely fail in its profitability efforts over the next year.
ELAN appears fairly valued based on a forward-looking basis, but this valuation is highly conditional. The forward P/E of 20.36x is not excessive for a company expected to grow earnings, but it is entirely dependent on the company hitting its estimated EPS of $1.535. On a Price-to-Sales basis, the PS ratio of 2.38 is near the low end of its own historical range, suggesting it is not overvalued relative to its past. The market is paying a fair price for the potential of a successful turnaround, but no margin of safety is present given the ongoing profitability challenges.
ELAN is a speculative buy only for investors with a high risk tolerance and a belief in the company's turnaround story. The stock offers potential upside if the company can stabilize profitability, as evidenced by its 12.16% revenue growth and reasonable forward P/E of 20.36x. However, it carries significant risk, including a recent $276M quarterly loss, severe gross margin compression, and high volatility (beta 1.687). It could be a good buy for aggressive growth portfolios if purchased on weakness, but investors should be prepared for a bumpy ride and size positions accordingly.
ELAN is primarily suited for a medium- to long-term investment horizon (2+ years) for investors betting on the turnaround narrative. The company's story requires multiple quarters to demonstrate whether it can achieve consistent profitability, making short-term trading highly risky due to earnings volatility and high beta (1.687). The stock does not pay a dividend, eliminating it as an income play. Given the volatility and the need for the thesis to play out, a minimum holding period of 12-18 months is suggested to weather inevitable quarterly swings and assess the fundamental progress.